



GWG TRAN Recommendations

Gil R Sambrano

Vice President of Portfolio Development and Review
California Institute for Regenerative Medicine

TRANSFORMING

*medicine
lives
futures*

May 24, 2018

Funding Opportunities



DISCOVERY



TRANSLATION



CLINICAL

New
Idea



Single Product
Candidate



Pre-IND Meeting
or Equivalent



Approved
Therapy



1-2/Year



3/Year



12/Year

Every Moment Counts | Don't Stop Now

CIRM Translation Research Program (TRAN)

Objective


To support promising stem cell-based projects that accelerate completion of translational stage activities necessary for advancement to clinical study or broad end use.

What qualifies for TRAN?

Projects that propose a candidate:

- Therapeutic (TRAN 1)
- Diagnostic (TRAN 2)
- Medical device (TRAN 3)
- Tool (TRAN4)

CIRM 2.0: Translation Program



Review Criteria

- ✓ Does the project hold the necessary significance and potential for impact?
- ✓ Is the rationale sound?
- ✓ Is the project well planned and designed?
- ✓ Is the project feasible?

Scoring System

- **Score of “85-100”**

Recommended for funding, if funds are available

- **Score of “1-84”**

Not recommended for funding

Applications are scored by all scientific members of the GWG with no conflict.

The **median** of all individual GWG scores determines final score.

GWG Recommendations

	Number of Apps	Total Applicant Request	Funds Available
Recommended for funding Score 85-100	4	\$14,157,655	\$30,000,000
Not recommended for funding Score 1-84	10		

For each award, the final award amount shall not exceed the amount approved by the ICOC Application Review Subcommittee and may be reduced contingent on CIRM's assessment of allowable costs and activities.

Overview of Recommended Applications

TRAN1-10958

TITLE: Autologous iPSC-derived smooth muscle cell therapy for treatment of urinary incontinence

DISEASE INDICATION: Urinary incontinence

PRODUCT TYPE: Cell therapy

APPROACH: Autologous, iPSCs-derived progenitor smooth muscle cells

TRAN2-10990

TITLE: Development of a Noninvasive Prenatal Test for Beta-Hemoglobinopathies for Earlier Stem Cell Therapeutic Interventions

DISEASE INDICATION: Beta-hemoglobinopathies

PRODUCT TYPE: Diagnostic

APPROACH: Non-invasive, Next Generation Sequencing of fetal DNA in maternal plasma

TRAN1-10937

TITLE: Therapeutic development of an oxysterol with bone anabolic and anti-resorptive properties for intervention in osteoporosis

DISEASE INDICATION: Osteoporosis

PRODUCT TYPE: Small molecule combination

APPROACH: Osteogenic compound combined with a bone-targeting and anti-resorptive agent

TRAN1-10995

TITLE: Morphological and functional integration of stem cell derived retina organoid sheets into degenerating retina models

DISEASE INDICATION: Retinitis pigmentosa

PRODUCT TYPE: Cell therapy

APPROACH: Transplant of hESC-derived retinal progenitor sheets